{"id":"nct:NCT06739226","kind":"trial","title":"Combination Immunotherapy Targeting Melanoma","authors":["Shenzhen Geno-Immune Medical Institute"],"author_count":1,"year":2024,"published":"2024-12-18","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT06739226","source_url":"https://clinicaltrials.gov/study/NCT06739226","archive_url":"https://space-kitty.com/papers/nct:NCT06739226","updated":"2026-08-27","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The purpose of this study is to assess the feasibility, safety and efficacy of combination immunotherapy based on CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell (DC) vaccines modified with GM-CSF and B7-2 (CD86) against melanoma, which targets CAR T specific surface antigens such as GD2, CTL specific antigens such as MAGE-A4, gp100 and a pool of melanoma specific antigens presented by the DCs. Another goal of the study is to learn more about the function and persistence of the CAR T cells and antigen-specific immune effectors in patients.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Melanoma"],"details":{"acronym":null,"status":"NOT_YET_RECRUITING","phase":"PHASE1, PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"sponsor":"Shenzhen Geno-Immune Medical Institute","conditions":["Melanoma"],"interventions":["BIOLOGICAL: Antigen-specific CAR T, CTL and DCvac to treat melanoma."],"start_date":"2027-06-30","start_date_type":"ESTIMATED","primary_completion_date":"2028-12-31","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}